VCG
JAZZ icon

Vantage Consulting Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Vantage Consulting Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-125
Closed -$21K – 833
2020
Q4 		$21K Buy
+125
New +$18.6K ﹤0.01% 850

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Vantage Consulting Group's JAZZ Position: Q1 2021 in Review

Vantage Consulting Group sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2021, closing a stake of 125 shares — an estimated $21K sold.

Vantage Consulting Group first reported a position in JAZZ in Q4 2020 and held it in 1 quarter. The position peaked at $21K in Q4 2020. 442 funds tracked by Wall St. Rank hold JAZZ as of Q1 2021.

  • Vantage Consulting Group reported no remaining Jazz Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Vantage Consulting Group sold 125 Jazz Pharmaceuticals shares in Q1 2021, an estimated $21K.
  • Vantage Consulting Group first reported a position in Jazz Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Vantage Consulting Group's Jazz Pharmaceuticals position peaked at $21K in Q4 2020.
  • 442 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.